Tags

Type your tag names separated by a space and hit enter

Breast cancer subtypes and the risk of local and regional relapse.
J Clin Oncol. 2010 Apr 01; 28(10):1684-91.JC

Abstract

PURPOSE

The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays.

PATIENTS AND METHODS

Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors.

RESULTS

The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis.

CONCLUSION

Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.

Authors+Show Affiliations

Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6. dvoduc@bccancer.bc.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20194857

Citation

Voduc, K David, et al. "Breast Cancer Subtypes and the Risk of Local and Regional Relapse." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 10, 2010, pp. 1684-91.
Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-91.
Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(10), 1684-91. https://doi.org/10.1200/JCO.2009.24.9284
Voduc KD, et al. Breast Cancer Subtypes and the Risk of Local and Regional Relapse. J Clin Oncol. 2010 Apr 1;28(10):1684-91. PubMed PMID: 20194857.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast cancer subtypes and the risk of local and regional relapse. AU - Voduc,K David, AU - Cheang,Maggie C U, AU - Tyldesley,Scott, AU - Gelmon,Karen, AU - Nielsen,Torsten O, AU - Kennecke,Hagen, Y1 - 2010/03/01/ PY - 2010/3/3/entrez PY - 2010/3/3/pubmed PY - 2010/4/10/medline SP - 1684 EP - 91 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 28 IS - 10 N2 - PURPOSE: The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays. PATIENTS AND METHODS: Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors. RESULTS: The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis. CONCLUSION: Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/20194857/Breast_cancer_subtypes_and_the_risk_of_local_and_regional_relapse_ L2 - https://ascopubs.org/doi/10.1200/JCO.2009.24.9284?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -